AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Bristol-Myers Squibb (BMY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

54.51

0.61 (1.13%)

At close: Feb 18, 2025, 3:59 PM

54.58

0.14%

After-hours: Feb 18, 2025, 07:55 PM EST

undefined% (undefined)

Bid	54.5
Market Cap	110.61B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.41
PE Ratio (ttm)	-12.36
Forward PE	n/a
Analyst	Hold

Ask	54.58
Volume	8,193,647
Avg. Volume (20D)	10,758,945
Open	53.72
Previous Close	53.90
Day's Range	53.54 - 54.59
52-Week Range	39.35 - 61.10
Beta	undefined

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for th...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Jun 1, 1972

Employees 34,100

Stock Exchange NYSE

Ticker Symbol BMY

Website https://www.bms.com

Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $61, which is an increase of 11.92% from the latest price.

Buy 21.43%

Hold 57.14%

Sell 14.29%

Stock Forecasts

Next Earnings Release

Bristol-Myers Squibb is scheduled to release its earnings on Apr 24, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-2.32%

Bristol-Myers Squibb shares are trading lower. The... Unlock content with Pro Subscription

1 week ago

-3.84%

Bristol-Myers Squibb shares are trading lower after the company issued FY25 revenue guidance below estimates.

News

2 days ago · seekingalpha.com

Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills

Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...

3 days ago · businesswire.com

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis.

6 days ago · businesswire.com

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial.

1 week ago · zacks.com

BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?

Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind.

1 week ago · benzinga.com

What's Going On With Bristol Myers Squibb Stock On Monday?

Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

1 week ago · zacks.com

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

1 week ago · seekingalpha.com

Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions. Despite a rece...

1 week ago · businesswire.com

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.

1 week ago · seekingalpha.com

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and concerns over patent expirations for key drugs. CEO Chris Boerner's multiyear plan focus...

1 week ago · marketbeat.com

Weak Guidance from Bristol-Myers Could Be Creating an Opportunity

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Load More News